Johnson & Johnson

Johnson & Johnson

Yahoo Finance • 13 hours ago

Woodside Pulls Back From Clean Energy: Is the New Strategy Bullish?

Woodside Energy Group Ltd (NYSE:WDS)'s first-half 2026 results point to a clear shift in strategy. The company reported a 7% increase in net profit to $1.33 billion, slightly ahead of expectations, while its average realized price rose to... Full story

Yahoo Finance • 13 hours ago

Johnson & Johnson (JNJ)’s Imaavy Expands Into Rare Blood Disorder: What Investors Should Know

The U.S. FDA has expanded Johnson & Johnson (NYSE:JNJ) approval of Imaavy to treat warm autoimmune hemolytic anemia (wAIHA), a rare and potentially life-threatening blood disorder. The approval covers patients aged 12 and older who are cur... Full story

Yahoo Finance • 13 hours ago

New FDA Approval Gives Bristol-Myers Squibb (BMY) Another Potential Oncology Growth Catalyst

The U.S. FDA has approved Bristol-Myers Squibb Company (NYSE:BMY)'s oral blood-cancer drug iberdomide, sold as Zenbexus, for patients with relapsed or refractory multiple myeloma. The treatment is given with Johnson & Johnson's Darzalex an... Full story

Yahoo Finance • 22 hours ago

Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves

An updated edition of the July 8, 2026, article. The global oncology market is undergoing significant transformation, driven by the rising burden of cancer, aging populations and rapid advances in medical science. According to the America... Full story

Yahoo Finance • 23 hours ago

What Is Johnson & Johnson (JNJ) Telling Investors With Its First WAIHA Approval?

Johnson & Johnson (NYSE: JNJ) received FDA approval for IMAAVY (nipocalimab-aahu) as the first treatment for warm autoimmune hemolytic anemia (wAIHA). The approval introduces the first therapy specifically shown to be safe and effective fo... Full story

Yahoo Finance • 2 days ago

Could Genmab (GMAB) Stock Win as Royalty Growth Fuels a New Earnings Cycle?

Genmab A/S (NASDAQ:GMAB) boosted its full-year 2026 revenue guidance to a range of $4.325 billion to $4.525 billion, up from its previous outlook of $4.065 billion to $4.395 billion. The upward revision underscores the strong commercial mo... Full story

Yahoo Finance • 2 days ago

Top Analyst Reports for JPMorgan, Johnson & Johnson & Mastercard

Wednesday, August 26, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Johnson & Johnson... Full story

Yahoo Finance • 2 days ago

Johnson & Johnson (JNJ) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Johnson & Johnson (JNJ) closed at $270.27 in the latest trading session, marking a -1.05% move from the prior day. The stock's change was less than the S&P 500's daily loss of 0.02%. Elsewhere, the Dow lost 0.21%, while the tech-heavy Nasd... Full story

Yahoo Finance • 2 days ago

J&J's First Anemia Approval Meets a $652 Billion Reality

This article first appeared on GuruFocus. Johnson & Johnson (NYSE:JNJ), the pharmaceutical and medical-technology giant, landed the first FDA approval for a treatment specifically targeting warm autoimmune hemolytic anemia. The breakthrou... Full story

Yahoo Finance • 2 days ago

Dividends vs. an Annuity: Which Turns $840,000 Into More Monthly Income for Life?

Quick Read A single-premium immediate annuity pays a 65-year-old roughly $5,250 to $5,600 a month for life, but the insurer permanently keeps the $840,000 principal. A dividend portfolio yields between $2,450 and $7,000 a month depending... Full story

Yahoo Finance • 2 days ago

Atrial Fibrillation Market Trends and Forecast 2026-2035 Featuring Profiles of Abbott, Boston Scientific, Medtronic, Johnson & Johnson, Novartis, and Sanofi

Company Logo Antiarrhythmic agents account for around 55% of the therapy landscape, while monoclonal antibodies are emerging as an investigational approach Atrial Fibrillation MarketAtrial Fibrillation Market Dublin, Aug. 26, 2026 (GLOB... Full story

Yahoo Finance • 2 days ago

Fidelity vs VanEck Healthcare ETFs: Broad Exposure or Pharma Focus

The Fidelity MSCI Health Care Index ETF (NYSEMKT:FHLC) provides broad, low-cost exposure to the entire healthcare sector, whereas the VanEck Pharmaceutical ETF (NASDAQ:PPH) offers a concentrated, higher-yielding focus on global pharmaceuti... Full story

Yahoo Finance • 2 days ago

How Much Do You Need Invested by 55 to Retire on Dividends at 65?

Quick Read To generate $50,000 annually from dividends at 65, a retiree needs roughly $1.43 million in a 3.5% dividend-growth portfolio by retirement. Higher yield tiers demand far less capital, such as $833,000 at 6% or $500,000 at 10%,... Full story

Yahoo Finance • 2 days ago

Atrial Fibrillation Treatment Devices Market Trends and Forecast, 2035 | Includes Profiles of Abbott, AtriCure, Boston Scientific, Johnson & Johnson, and Medtronic

Company Logo Opportunities center on pulsed field ablation, advanced mapping catheters and LAAC implants, driven by aging populations and demand for safer, drug-free care. Asia-Pacific expansion, ambulatory procedures, improving reimburse... Full story

Yahoo Finance • 2 days ago

5 Blue-Chip Dividend Stocks to Buy Before August Ends

Quick Read JNJ targets $21 billion in free cash flow this year while KO posted its strongest volume growth in 17 years and raised full-year EPS guidance. XOM's Guyana field just recovered its $55 billion investment and now generates free... Full story

Yahoo Finance • 3 days ago

J&J's First-In-Disease Approval Barely Moves a $666 Billion Stock

This article first appeared on GuruFocus. Johnson & Johnson (NYSE:JNJ), the pharmaceutical and medical-technology powerhouse, held roughly flat at $273.24 Tuesday morning after the FDA approved Imaavy for warm autoimmune hemolytic anemia.... Full story

Yahoo Finance • 3 days ago

J&J's Imaavy Gets FDA Approval as the First Treatment for wAIHA

Johnson & Johnson JNJ announced that the FDA has approved Imaavy (nipocalimab-aahu) for the treatment of warm autoimmune hemolytic anemia (wAIHA) in adults and pediatric patients aged 12 years and above who are currently or have been previ... Full story

Yahoo Finance • 3 days ago

The Floor Under BSX Stock Is Being Tested Again

Photo by Pexels on Pixabay Boston Scientific is back on familiar ground, but the business arriving this time is not the same. Will a history of strong bounces matter more than a future of weaker growth? Boston Scientific (BSX), a maker o... Full story

Yahoo Finance • 3 days ago

Johnson & Johnson Is Near a Record High. Is There Still Room to Run?

Quick Read JNJ trades at $270, inches from its $276 52-week high, with raised guidance and FDA robotic approval already priced into analyst consensus. JNJ's 32% YTD gain nearly triples SPY's 12% return, yet a trailing P/E of 31 leaves lit... Full story

Yahoo Finance • 3 days ago

LLY vs. ABBV: Which Stock Has the Stronger Growth Prospects?

Eli Lilly LLY and AbbVie ABBV are leading U.S. drugmakers with established portfolios, blockbuster therapies, robust R&D pipelines, large market capitalizations and a strong global presence. Both have significant exposure to major therapeu... Full story